Japan Committee Recommends Lecanemab Approval
Possible Late November Launch?
Executive Summary
An advisory committee of Japan’s MHLW has given a favourable opinion for the approval of Eisai's Alzheimer's drug lecanemab, setting the stage for a possible full official approval in September, after which it would be co-commercialized with global partner Biogen.